


Supplementary Figures


Supplementary Figure 1



Supplementary Figure 1 *ARHGAP33* mRNA localization.

(a, b) Fluorescent *in situ* hybridization for *ARHGAP33* mRNA in a sagittal section of adult WT mice (a) and *ARHGAP33* KO mice (a, inset). Higher magnification of the hippocampus is shown in b. Cb, cerebellum; CP, caudate-putamen; CX, cerebral cortex; Hi, hippocampus; MB, midbrain; MO, medulla oblongata; OB, olfactory bulb; Th, thalamus. CA, cornu ammonis; DG, dentate gyrus; Gr, granule cell layer; Or, oriens layer; Py, pyramidal cell layer; Ra, radiatum layer. Scale bars, 1 mm (a), 500 μ m (b). (c-f) Fluorescent *in situ* hybridization for *ARHGAP33* mRNA together with *VGLUT1* mRNA (c) and *GAD67* mRNA (e) in the dentate gyrus of the hippocampus. Gr, granule cell layer; ML, molecular layer; Pl, polymorphic layer. Scale bars, 20 μ m. (g-j) Fluorescent *in situ* hybridization for *ARHGAP33* mRNA together with *VGLUT1* mRNA (g) and *GAD67* mRNA (i) in the CA1 region of the hippocampus. LM, stratum lacunosum-moleculare; Or, Stratum oriens; Py, pyramidal cell layer; Ra, stratum radiatum. Scale bars, 20 μ m. Note that *ARHGAP33* mRNA was colocalized both with *VGLUT1* mRNA and *GAD67* mRNA (arrow head) in the dentate gyrus and the CA1 region of the hippocampus (c, e, g, i).


Supplementary Figure 2



Supplementary Figure 2 Generation of *ARHGAP33* KO mice.

(a) Schematic representation of the wild-type allele, targeting vector, and the targeted *ARHGAP33* allele. Neo, neomycin-resistant gene; PGK, phosphoglycerate kinase promoter; TK, thymidine kinase gene. (b) Immunoblotting for *ARHGAP33* in adult wild-type and *ARHGAP33* KO mouse brain lysates. Tubulin was used as a loading control. (c) Normal body size of *ARHGAP33* KO mice compared to WT mice (WT, $N = 14$; *ARHGAP33* KO, $N = 14$; $P > 0.05$, Mann-Whitney U-test). Bars show median values. (d) Nissl staining in coronal brain sections including hippocampus of adult WT and *ARHGAP33* KO mice. Higher magnifications of the hippocampus are shown in the right panels. Scale bars, 1 mm.


Supplementary Figure 3



Supplementary Figure 3 Normal behavior of *ARHGAP33* KO mice.

(a) The rotarod test. The average of time spent on the rotarod across 8 test trials for WT (open circles) and *ARHGAP33* KO (closed circles) mice (WT, $N = 12$, *ARHGAP33* KO, $N = 11$). There were no significant differences between the two genotypes ($P > 0.05$, repeated-measures ANOVA). The data are expressed as mean \pm s.e.m. (b) The open field test. Normal locomotor activity in *ARHGAP33* KO mice (closed circles) in the open field test compared to WT mice (open circles) (WT, $N = 14$, *ARHGAP33* KO, $N = 14$). There were no significant differences between the two genotypes ($P > 0.05$, Two-way ANOVA with repeated measures). The data are expressed as mean \pm s.e.m. (c, d) The contextual fear conditioning test. Freezing responses on the conditioning day (c). 170 s after the placement of mice in the conditioning chamber, a tone was presented for 10 s (solid line); at the end of the tone, mice were given a footshock for 2 s (arrow). Freezing responses in the contextual fear conditioning test (WT, $N = 14$, *ARHGAP33* KO, $N = 12$, $P > 0.05$, Two-way ANOVA with repeated measures) (d). There were no significant differences between the two genotypes ($P > 0.05$, Two-way ANOVA with repeated measures). The data are expressed as mean \pm s.e.m. (e, f) The Morris water maze test. The escape latency in the training session (WT, $N = 14$, *ARHGAP33* KO, $N = 12$, $P > 0.05$, Two-way ANOVA with repeated measures) (e). The time spent in each quadrant during the probe trials (WT, $N = 14$, *ARHGAP33* KO, $N = 12$, $P > 0.05$, Mann-Whitney U-test) (f). Bars show median values. (g) The elevated plus-maze test. The time spent on open arms (WT, $N = 14$, *ARHGAP33* KO, $N = 12$, $P > 0.05$, one-way ANOVA) (left). Entries into open arms (WT, $N = 14$, *ARHGAP33* KO, $N = 12$, $P > 0.05$, one-way ANOVA) (right). Bars show mean values. (h) Responses to acoustic stimuli. Mean amplitudes of startle responses in WT (open circles) and *ARHGAP33* KO (closed circles) mice (WT, $N = 12$, *ARHGAP33* KO, $N = 11$) are shown. There were no significant differences between the two genotypes ($P > 0.05$, Two-way ANOVA with repeated measures). The data are expressed as mean \pm s.e.m. N.S., not significant.

Supplementary Figure 4




Supplementary Figure 4 Effects of SORT1 knockdown with shRNA construct

(TRCN0000034494).

(a) Weakened interaction between ARHGAP33 and TrkB in the SORT1 knockdown neuron. ARHGAP33 immunoprecipitates and total lysates were immunoblotted with the indicated antibodies. Representative blots (left), quantification of co-immunoprecipitated TrkB (center), and quantification of SORT1 expression (right)


(each $N = 7$; TrkB, $P = 0.0017$, SORT1, $P = 0.0017$, Mann-Whitney U-test). The averaged values of the control neurons were set to 100%. Bars show median values. Western blots show representative results from 7 independent experiments performed using neurons from different mice. cont., control. KD, knockdown. Note that another shRNA construct (TRCN0000034494) targeted to region of SORT1 that does not overlap with that targeted by the shRNA used in Fig. 7c was used. **(b)** Requirement of SORT1 in ARHGAP33-mediated TrkB trafficking. Biotinylated cell surface proteins and total lysates were immunoblotted with the indicated antibodies. Representative blots (left) and quantification of surface TrkB expression (right) (each $N = 10$; WT vs *ARHGAP33* KO in the control neurons, corrected $P = 6.2 \times 10^{-4}$; WT vs *ARHGAP33* KO in the SORT1 knockdown neurons, corrected $P > 0.05$, Mann-Whitney U-test with the Ryan's correction). The averaged values of the control neurons from WT mice were set to 100%. Western blots show representative results from 10 independent experiments performed using neurons from different mice. cont., control. KD, knockdown. Bars show median values. Note that another shRNA construct (TRCN0000034494) targeted to region of SORT1 that does not overlap with that targeted by the shRNA used in Fig. 7c was used.

Supplementary Figure 5



Supplementary Figure 5 Original uncropped images of western blots.

Supplementary Figure 5 (continued)



Supplementary Figure 5 (continued) Original uncropped images of western blots.

Supplementary tables

Supplementary Table 1. Demographic information for patients with schizophrenia and healthy controls included in expression analysis

Variables	Schizophrenia (<i>N</i> = 45)	Control (<i>N</i> = 45)
Age (years)	32.3 ± 10.7	32.3 ± 12.7
Sex (male/female)	29/16	29/16
CPZ-eq (mg/day)	737.7 ± 587.1	-
Age at onset (years)	22.2 ± 8.5	-
Duration of illness (years)	9.9 ± 7.8	-
PANSS Positive Symptoms	24.0 ± 7.3	-
PANSS Negative Symptoms	25.8 ± 8.6	-
PANSS General Psychopathology	54.3 ± 14.1	-

PANSS, Positive and Negative Syndrome Scale;

CPZ-eq, chlorpromazine equivalent of total antipsychotics. Mean ± s.d.

Supplementary Table 2. Demographic information for patients with schizophrenia and healthy controls included in brain structure analysis

Variables	Schizophrenia (<i>N</i> = 124)	Control (<i>N</i> = 407)	<i>P</i> values (<i>z</i>)
Age (years)	37.5 ± 12.3	35.4 ± 12.5	0.055 (1.9)
Sex (male/female)	70/54	191/216	0.063 (3.4) ^a
Education (years)	14.1 ± 2.3	15.0 ± 2.2	<0.001 (-3.2)
Estimated premorbid IQ	101.9 ± 10.1	107.6 ± 8.1	<0.001 (-5.6)
Handedness (Rt./Lt./Bil.)	120/4/0	383/23/1	0.48 (1.5) ^a
CPZ-eq (mg/day)	572.8 ± 536.4	-	-
Age at onset (years)	24.9 ± 10.2	-	-
Duration of illness (years)	12.5 ± 9.8	-	-
PANSS Positive Symptoms	18.5 ± 5.7	-	-
PANSS Negative Symptoms	19.3 ± 6.2	-	-
PANSS General Psychopathology	40.6 ± 11.1	-	-

PANSS, Positive and Negative Syndrome Scale; CPZ-eq, chlorpromazine equivalent of total antipsychotics. Mean ± s.d. and *p* values are shown. Significant *P* values are shown as bold face and underlined. ^a χ^2 test. Complete demographic information was not obtained for all subjects (estimated premorbid IQ and PANSS in patients: *N* = 115 and *N* = 122; estimated premorbid IQ in controls: *N* = 406).

Supplementary Table 3. Effects of *ARHGAP33* genotype-diagnosis interaction on brain structure in total subjects

Brain regions	R/L	BA	CS	<i>T</i>	corrected <i>p</i> value	Talairach coordinates		
						<i>x</i>	<i>y</i>	<i>z</i>
<i>ARHGAP33</i> genotype-diagnosis interaction								
Middle Temporal Gyrus	L	21	286	4.39	7.2×10^{-4}	-49	6	-35
Medial Frontal Gyrus	R	25	555	4.26	1.1×10^{-3}	5	16	-13
Inferior Temporal Gyrus	R	20	451	3.69	8.5×10^{-3}	57	-12	-20

R, right; L, left; BA, Brodmann area; CS, Cluster size; T, Peak-voxel T.

Supplementary Methods

Nucleotide sequence of the cRNA probe of *ARHGAP33* for *in situ* hybridization

5' -

```
ATGCTCCAGA CACAGAGAGA GTCAGATCCC ATCCTGCCTT GGGGAGCTTC ATGGGCTGGC AGGGGACAGA CCCTGAGGGC CCGAAGCACT
GACAGCCTGG ATGGCCCAGG GGAGGGCTCA GTGCAGCCTG TTCCTCTAC TGGAGGGCCC AGTGTGAAGG GGAAGCCTGG GAAGAGGCTC
TCAGCTCCTC GAGGTCCTTT TCCTCGGCTG GCGACTGTG CCCATTTCCA CTATGAGAAT GTTGACTTTG GCCATATTCA GCTCCTACTG
TCTCCAGAGC GTGAAGGCC CAGCCTCTCT GGAGAGAATG AGTGTGTATT TGGGGTGCAG GTAACCTGTC AGGGCCGTTT TTGGCCAGTT
CTTCGTAGTT ACGATGACTT CCGTTCCTCT GATGCCCACC TGCACCGATG CATATTTGAC CCGAGGTTTT CTGCCTTCC AGAGCTCCCT
CCACCCCCAG AGGGTGTCTG GGCTGCCCAG ATGCTGGTAC CTCTGTGCT GCAGTATCTG GAGACCCTGT CTGGACTGGT GGACAGTAAC
CTCAACTGTG GGCCTGTGCT CACTTGGATG GAGCTGGACA ATCATGGCCG ACGATTGCTC CTCAGTGAGG AGGCCTCCCT CAATATCCCT
GCAGTGGCTG CCGCTCATGT GGTCAAACGG TACACAGCTC AGGCACCAGA TGAGCTCTCC TTTGAGGTGG GAGACATCGT CTCAGTGATC
GACATGCCAC CCACAGAGGA TCGGAGCTGG TGGCGGGCA AGCGGGGCTT CCAGGTTGGT TTCTTCCCA GCGAGTGTGT AGAAGTCTTC
ACAGAGAGGC CAGGTCTGCG CTTAAAGGCA GATGCTGATG GTTCCCTGTG TGGCATCCCA GCTCCCCAGG GTAACCTTTC TCTCACCTCA
GCTGTGCCCC GGCCACGTGG GAAGCTGGCT GGCTCCTCC GAACCTTCAT GCGCTCCCGC CTTCTCGGC AGCGGTTGCG GCAGCGGGGA
ATTCTGCGGC AGAGAGTATT TGGCTGTGAC CTGGAGAGC ATCTCAGCAA CTCAGGCCAG GATGTGCCCC AAGTGTGCG CTGCTGCTCT
GAGTTTATTG AGGCCATGG GGTGGTGGAT GGAATCTACC GGCTCTCAGG CGTGTCTCC AACATCCAGA GGCTACGGCA TGAATTTGAC
AGTGAGAGGA TTCCTGAAC ATCTGGCCCT GCCTTCCCTG AGGACATCCA CAGTGTATCC TCCCTTTGCA AACTCTACTT CCGAGAGCTA
CCAAACCCCT TACTCACCTA CCAGCTCTAT GGGAAATFCA GTGAGGCCAT GTGAGTCCTA GGGGAGGAAG AACGCCTGGT GAGAGTCCAT
GATGTCATCC AGCAGTTGCC CCCACCACAC TACAGGACTC TAGAGTACCT GCTGAGGCAC TTGGCCCCGA TGGCAAGACA TAGTGCCAA
ACCAGCATGC ATGCCCGCAA CTTGGCCATT GTCTGGGCAC CCAACCTGCT CCGGTCCATG GAGCTAGAGT CAGTGGGGCT GGGTGGGGCG
GCAGCCTTCC GGGAGGTTCC TGTGCAGTCA GTGGTGGTGG AATTCCTGCT CACCCATGTG GAGTCTCTGT TTAGTGACAC CTTCACTCTC
GCTGGCTAG ACCCTGCAGG CCGCTGTCTT CTCCCAGGC CCAAGTCCCT TGGGGGAAGT GGCCCTCTA CTCGCTGCTT CACCTGTGGA
GAAGCCAGG CTCGTACCCA GGGCCGGCTG GGAACACCCA CTGAGCCAC AACTCTCAAG GCTGCAGCT CACCTGTGGA AAAGAGGAAA
AGGGAGAGAG GGGAAAACA GCGGAAGCCA GGGGGCAGCA GCTGGAAGAC ATTCTTTGCT CTTGGCCGGG GCCCCAGCAT CCCCCGGAAG
AAGCCTCTAC CCTGGCTGGG GGGCTCTCGT GCACCACCAC AGCCTTCAGG CAACCGACT GACACAGTCA CACTGAGGTC GGCTAAGAGT
GAAGAGTCTC TATCATCACA GGCCAGTGG ACTGGCCTCC AGAGGCTACA CAGGCTACGG CGACCCACT CCAGCAGCGA TGCTTTCCCA
GTGGGCCAG CACCTGTGCG CTCTGCGAG ACCCTGTCTT CTTCTTCTC TTCTTCTCC TCCTCGTCAG CTTCTCTC ATCATCATCA
TCTGAGTCTC CAGCAGTGG GCTGGGGCCA CTTTCCGGGT CACCCTACA TCGACCTCA GCCTGGCTAG ATGATGGTGA TGAAGTGGAC
TTTAGCCAC CCCGCTGCCT GGAGGGACTC CGGGGCTGG ACTTTGATCC GCTTACCTTT CGCTGCAGCA GCCCCACCC AGGGGACCC
GCACCTCTG CCAGCCAGC ACCCCAGCA CCCGCTCTG CCTGCCACC CAGGGCAACC CCCAAGGCTC CCTCACCCG AGGACCCACC
AGCCAGCTT CGTCCACTGC TCTGGACATC TCAGAGCCCC TGGCTGTGTC GTACCACCT GCTGTCTTAG AACTGCTGGG GGCAGGAGGA
ACACCTGCCT CGGTCACCC AACACCAGCT CTCAGCCCTG GCCCAGGCTT GCGCCCCAT CTCATCCCTT TGCTGTGCA TGGATCAGAG
GCCCAGCTAA GTGACACCT CCAACAAGAG ATCAGCAGTA AGTGGCCTT GCCTGGTCTT GGGGAAGC AAGTCTCTGG TATAGATTCA
CCATTGCTGC CCCCACTCT GTCCCTTCTA CGCCCTGGTG GGGCCCCC AAGAACGCAG CGCGCTCAT GGCACCTGGC
CTGGCTGAGC GGGCTCAGCA GGTGGCTAAG CAACAGAGCC AGCAGGAGCA TGCAAGCACC TCAACTAGTC CACACTCCCC TTTCCGCCGT
TCACTGTCCC TGGAGGTCGG TGGGGAACCT GTGGTAACTT CAGGGAGTGG ACCACCCCT CACTCCCTAG CCCACCCTGG TGTCTGGGCC
CCAGGACCCC CACCCTACT ACCAAGGCAA CAAAGTGATG GGAGCCTGGT ACGGAGCCAG CGGCTGTGG GGACCTCAAG GAGGGGTCTC
AGAGGCCCTG CTCAGGTTCC TACCCCTAGT GTCTTTTCTC CAGCTCCCG GGAGTGCCTG CCACCTTTC TTGGGGTCTC CAAACCAGGC
TTGTACCTC TCGCCCTC CTCTTTTCAA CCAACTCCT CAGCCAAAGT CTGGAGGAAT TCTCTGGGC CCCCTGCACC TCTTGACAGG
GGAGAGAACC TGTACTATGA GATTGGGGCT AGTGAGGGTT CCCCTATTC TGGGCCACT CGGTCCTGGA GTCCTTTTCG CTCCATGCC
CCTGATAGG TCAGTGCCCT ATATGGCATG CTGGCCAGT CACCACCCT TCACAGGTCA CCTGACTTCC TGCTCAGTA CCCACCGCC
CCCTCTGCT TTCCACCTGA CCACCTTGG TATTCTGGTCC CCCAGCACC TGCCCGGCAC CCTACCCGGC CAGAGCCCT CTATGTCAAC
CTAGCCCTAG GGCCAGGGG TCCTTACCT GCCTTCTCT GCTCTCTTC CCCTCTGCC CATCCAGAA GTCGTTGGA TCCTGGGCC
CCAGCACCTC GTCTCCCTCA GAAGCAGCG GCTCCCTGG GCTCCAATAC CCCTCATAGG GTAACAGGAC CTTGGGGCC TCCTGAACCT
CTCTGTCTCT ACAGGGGATC CCCACCAGC TATGGGAGG GGAGCGAGCA TTACCAAGG TCTTTGTACA GAAATGGGG TCAGAGGGGA
GAGGGGGCTG GTCCTCCACC TCCTTACCTC ACTCCAGTT GGTCCCTCCA CTCTGAGGC CAGACCCGAA GCTACTGTTG A-3'
```